Serial 79435549
Live / Registered — Registered (as of 21 Apr 2026)
What this means for you
Registered since 21 Apr 2026. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 21 Apr 2032: the §71 affidavit of use).
Record
- Serial number
- 79435549
- Registration number
- 8217704
- Mark type
- Design / logo
- Filed
- 24 Sept 2025
- Published for opposition
- 03 Mar 2026
- Registered
- 21 Apr 2026
- Next maintenance filing
- §71 affidavit of use, due by 21 Apr 2032 (grace period to 21 Oct 2032)
- Attorney of record
- Ben Natter
Goods and services
- Class 001 — Chemicals: Chemicals for use in industry and science; biochemicals, namely, polypeptides and engineered antibodies for scientific, laboratory or research purposes; polypeptides and engineered antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for scientific, laboratory or research purposes; ion channel modulating or G-protein-coupled receptor modulating engineered antibodies for use in the manufacture of pharmaceuticals and drugs; engineered antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; engineered antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs
- Class 005 — Pharmaceuticals: Pharmaceuticals and pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including preparations for the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; drugs, namely, pharmaceutical preparations for the treatment of diseases and conditions associated with dysregulation of ion channel or G-protein-coupled receptor activity, including those for use in the prevention and treatment of pain, autoimmunity, cardiovascular disease and cancer; engineered antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating engineered antibodies, ion channel modulating or G-protein-coupled receptor modulating engineered antibodies or engineered antibodies derived from mini-protein toxins; vaccines
- Class 042 — Scientific and technological services: Scientific and technological services, namely scientific research, analysis and testing in the fields of pharmaceuticals, biochemicals, polypeptides, antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies and antibodies derived from mini-protein toxins; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; scientific and medical research laboratory services relating to the production of antibodies, ion channel modulating or G-protein-coupled receptor modulating antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific research services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid
- Class 044 — Medical, beauty and agricultural services: Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid
Owner
Prosecution history
- 15 Oct 2026 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 27 Sept 2026 — FINAL DISPOSITION NOTICE SENT TO IB
- 27 Sept 2026 — FINAL DISPOSITION PROCESSED
- 21 Jul 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 21 Apr 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Apr 2026 — REGISTERED-PRINCIPAL REGISTER
- 03 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Mar 2026 — PUBLISHED FOR OPPOSITION
- 25 Feb 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Feb 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Feb 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 05 Feb 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 05 Feb 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 01 Jan 2026 — REFUSAL PROCESSED BY IB
- 18 Dec 2025 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB